Seropositivity for neutralizing antibodies against A9 and A7 pseudoviruses at entry (Month 0).^a

a<p>Cervarix n = 94; Gardasil n = 93</p

CONSORT diagram.

<p>Allocations, interventions, follow up and analysis of 198 subjects recruited into the comparative HPV vaccine immunogenicity study.</p

Neutralizing antibody responses over time course of study.

<p>Percentage of vaccinees with neutralization titers of ≥20 (left panels) and GMT (right panels) against indicated vaccine (HPV16, HPV18) and non-vaccine (HPV31, HPV45) types. Error bars, ±95% CI. * <i>p</i><0.05; ** <i>p</i><0.01; *** <i>p</i><0.001. Denominators for each measure were as follows: Cervarix® (blue) M0 (n = 94), M2 (n = 91), M7 (n = 91), M12 (n = 92); Gardasil® (red) M0 (n = 93), M2 (n = 98), M7 (n = 97), M12 (n = 96).</p

Relationship between HPV-specific vaccine antibodies in sera and genital samples.

<p>(A) Neutralization titers were normalized to IgG levels in serum and genital samples for HPV16 (left panel; Cervarix® n = 21, Gardasil® n = 28) and HPV18 (right panel; Cervarix® n = 21, Gardasil® n = 26). (B) VLP binding titers were normalized to IgG levels in serum and genital samples for HPV16 (top left panel; Cervarix® n = 20, Gardasil® n = 21), HPV18 (top right panel; Cervarix® n = 19, Gardasil® n = 21), HPV31 (bottom left panel; Cervarix® n = 14, Gardasil® n = 21) and HPV45 (bottom right panel; Cervarix® n = 17, Gardasil® n = 24). Geometric mean ratios of the HPV specific IgG/total IgG for each sample type presented for Cervarix® (blue lines) and Gardasil® (red lines). (C) Relationship between serum and genital samples using normalized neutralizing and binding antibody for all tests. Overall Pearson's (<i>r</i>) coefficients are given. PsV, HPV pseudovirus. VLP, HPV virus-like particle.</p

Peak seropositivity and geometric mean neutralizing antibody titers against A9 and A7 HPV pseudoviruses (Month 7).^a

a<p>Cervarix n = 91; Gardasil n = 97. <i>p</i> values <0.05 highlighted in bold type. N/A, not applicable</p

Breadth of neutralizing antibody responses elicited by HPV vaccines.

<p>Percentage of serum samples neutralizing indicated number of A9 (top panel) or A7 (bottom panel) non-vaccine types within each of the low (T1), middle (T2) or high (T3) vaccine-type tertiles (dark to light gradient shading) for indicated vaccine (blue, Cervarix®; red, Gardasil®).</p

Treatment and clinical progression during admission.

<p>Treatment and clinical progression during admission.</p

Demographic and clinical features at enrolment.

<p>Demographic and clinical features at enrolment.</p

CONSORT Flow Diagram.

<p>Consort diagram of patients eligible, recruited, numbers followed up and included in analysis.</p

Survival plot with futility boundary for TKM-130803 recipients.

<p>The red line denotes the futility boundary. The points and dashed line denote the number of survivors at day 14 plotted against the number of day 14 reports.</p